Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Makker V, Colombo N, Casado A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Yonemori K, Kim YM, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kristeleit R, Nishio S, Suzuki S, Guerra Alía EM, Sanli UA, Selle F, Shikama A, Martínez Rodríguez JL, Arik Z, Arican A, Sebastianelli A, Yu Z, McKenzie J, Kruger S, Meng R, Okpara CE, Lorusso D

Open source

DOI: 10.1136/jitc-2025-013713
Published: 2026 Feb 19
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2025-013713,
  title = {Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.},
  author = {Makker V and Colombo N and Casado A and Santin AD and Colomba E and Miller DS and Fujiwara K and Pignata S and Yonemori K and Kim YM and Baron-Hay S and Ray-Coquard I and Shapira-Frommer R and Kristeleit R and Nishio S and Suzuki S and Guerra Alía EM and Sanli UA and Selle F and Shikama A and Martínez Rodríguez JL and Arik Z and Arican A and Sebastianelli A and Yu Z and McKenzie J and Kruger S and Meng R and Okpara CE and Lorusso D},
  year = {2026},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2025-013713},
  url = {https://doi.org/10.1136/jitc-2025-013713}
}

RIS

TY  - JOUR
TI  - Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.
AU  - Makker V
AU  - Colombo N
AU  - Casado A
AU  - Santin AD
AU  - Colomba E
AU  - Miller DS
AU  - Fujiwara K
AU  - Pignata S
AU  - Yonemori K
AU  - Kim YM
AU  - Baron-Hay S
AU  - Ray-Coquard I
AU  - Shapira-Frommer R
AU  - Kristeleit R
AU  - Nishio S
AU  - Suzuki S
AU  - Guerra Alía EM
AU  - Sanli UA
AU  - Selle F
AU  - Shikama A
AU  - Martínez Rodríguez JL
AU  - Arik Z
AU  - Arican A
AU  - Sebastianelli A
AU  - Yu Z
AU  - McKenzie J
AU  - Kruger S
AU  - Meng R
AU  - Okpara CE
AU  - Lorusso D
PY  - 2026
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2025-013713
UR  - https://doi.org/10.1136/jitc-2025-013713
ER  -

APA

V, M., N, C., A, C., AD, S., E, C., DS, M., K, F., S, P., K, Y., YM, K., S, B., I, R., R, S., R, K., S, N., S, S., EM, G. A., UA, S., F, S., A, S., JL, M. R., Z, A., A, A., A, S., Z, Y., J, M., S, K., R, M., CE, O., & D, L. (2026). Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2025-013713

Source records

pubmed · retrieved 2026-09-25T06:07:31.224Z